Organoids Research for Colorectal Cancer: Promising Approach for
Precision Medicine, their Applications and Future Perspectives

Sonia      Singh; Ashima      Ahuja; Raghavan      Ramankutty; Sarada      Ramaswamy

doi:10.2174/0115748855266739230919110125

Abstract

Background: Organoids are three-dimensional (3D) constructs designed to emulate the complexity and functionality of organs in the body. Organoids have recently been used as powerful instruments for modeling and investigating several diseases, including colorectal cancer. Colorectal cancer is caused by altering colonic epithelial cells, which produce adenomas and carcinomas.

Objective: The objective of present study was to investigate impact of organoids on colorectal cancer and their therapeutic outcome in cancer research. Organoids can be grown from stem cells in vitro, which closely resemble the structure and function of the organ they are derived from. They have been used in a variety of research applications, including disease modeling, drug screening, and personalized medicine. Organoids have allowed researchers to understand better the mechanisms underlying colorectal cancer initiation, progression, and resistance to therapy.

Methods: The literature review was surveyed, and keywords related to cancer management, organoids, modelling, personized medicine, 3D structures were screened for colorectal cancer management were screened in SCI-hub, SCOPUS, WOS, and ABC Journals.

Results: The findings of studies suggested that organoids derived from patient tumors can recapitulate the histopathology and genetic alterations of the original tumor, making them a valuable tool for personalized medicine.

Conclusion: Organoids have been used to develop high-throughput drug screening assays and investigate the tumor microenvironment's contribution to colorectal cancer progression. In this review, we summarize recent advances in the use of organoids to study colorectal cancer and discuss their potential applications in the clinic.

Keywords: Organoids, 3D, colorectal cancer, modeling, personalized medicine, epithelial cells.

« Previous Next »

Graphical Abstract

[1]
Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol  2019; 16(12): 713-32.
 [http://dx.doi.org/10.1038/s41575-019-0189-8]

[2]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2018; 68(6): 394-424.
 [http://dx.doi.org/10.3322/caac.21492]

[3]
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut  2017; 66(4): 683-91.
 [http://dx.doi.org/10.1136/gutjnl-2015-310912]

[4]
Yang T, Li X, Montazeri Z, et al. Gene–environment interactions and colorectal cancer risk: An umbrella review of systematic reviews and meta‐analyses of observational studies. Int J Cancer  2019; 145(9): 2315-29.
 [http://dx.doi.org/10.1002/ijc.32057]

[5]
Roney MSI, Lanagan C, Sheng YH, et al. IgM and IgA augmented autoantibody signatures improve early‐stage detection of colorectal cancer prior to nodal and distant spread. Clin Transl Immunology  2021; 10(9): e1330.
 [http://dx.doi.org/10.1002/cti2.1330]

[6]
Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal cancer incidence patterns in the United States, 1974–2013. J Natl Cancer Inst  2017; 109(8): djw322.
 [http://dx.doi.org/10.1093/jnci/djw322]

[7]
Alves Martins BA, de Bulhões GF, Cavalcanti IN, Martins MM, de Oliveira PG, Martins AMA. Biomarkers in colorectal cancer: the role of translational proteomics research. Front Oncol  2019; 9: 1284.
 [http://dx.doi.org/10.3389/fonc.2019.01284]

[8]
Jung E, Choi J, Kim JS, Han TS. MicroRNA-based therapeutics for drug-resistant colorectal cancer. Pharmaceuticals (Basel)  2021; 14(2): 136.
 [http://dx.doi.org/10.3390/ph14020136]

[9]
Zhou J, Su J, Fu X, Zheng L, Yin Z. Microfluidic device for primary tumor spheroid isolation. Exp Hematol Oncol  2017; 6(1): 22.
 [http://dx.doi.org/10.1186/s40164-017-0084-3]

[10]
Mittal R, Woo FW, Castro CS, et al. Organ‐on‐chip models: Implications in drug discovery and clinical applications. J Cell Physiol  2019; 234(6): 8352-80.
 [http://dx.doi.org/10.1002/jcp.27729]

[11]
Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature  2009; 459(7244): 262-5.
 [http://dx.doi.org/10.1038/nature07935]

[12]
Fatehullah A, Tan SH, Barker N. Organoids as an in vitro model of human development and disease. Nat Cell Biol  2016; 18(3): 246-54.
 [http://dx.doi.org/10.1038/ncb3312]

[13]
Xu H, Jiao Y, Qin S, Zhao W, Chu Q, Wu K. Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine. Exp Hematol Oncol  2018; 7(1): 30.
 [http://dx.doi.org/10.1186/s40164-018-0122-9]

[14]
Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid technology and applications in cancer research. J Hematol Oncol  2018; 11(1): 116.
 [http://dx.doi.org/10.1186/s13045-018-0662-9]

[15]
Li M, Izpisua Belmonte JC. Organoids—preclinical models of human disease. N Engl J Med  2019; 380(6): 569-79.
 [http://dx.doi.org/10.1056/NEJMra1806175]

[16]
Pastrana E. The developing human brain—modeled in a dish. Nat Methods  2013; 10(10): 929.
 [http://dx.doi.org/10.1038/nmeth.2674]

[17]
Lancaster MA, Huch M. Disease modelling in human organoids. Dis Model Mech  2019; 12(7): dmm039347.
 [http://dx.doi.org/10.1242/dmm.039347]

[18]
Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science  2019; 364(6444): 952-5.
 [http://dx.doi.org/10.1126/science.aaw6985]

[19]
Shi R, Radulovich N, Ng C, et al. Organoid cultures as preclinical models of non-small cell lung cancer. Clin Cancer Res  2020; 26(5): 1162-74.
 [http://dx.doi.org/10.1158/1078-0432.CCR-19-1376]

[20]
Xuefeng X, Hou MX, Yang ZW, et al. Epithelial–mesenchymal transition and metastasis of colon cancer cells induced by the FAK pathway in cancer-associated fibroblasts. J Int Med Res  2020; 48(6)
 [http://dx.doi.org/10.1177/0300060520931242]

[21]
Chaiyawat P, Chokchaichamnankit D, Lirdprapamongkol K, Srisomsap C, Svasti J, Champattanachai V. Alteration of O-GlcNAcylation affects serine phosphorylation and regulates gene expression and activity of pyruvate kinase M2 in colorectal cancer cells. Oncol Rep  2015; 34(4): 1933-42.
 [http://dx.doi.org/10.3892/or.2015.4178]

[22]
Vickers NJ. Animal communication: when i’m calling you, will you answer too? Curr Biol  2017; 27(14): R713-5.
 [http://dx.doi.org/10.1016/j.cub.2017.05.064]

[23]
Lau HCH, Kranenburg O, Xiao H, Yu J. Organoid models of gastrointestinal cancers in basic and translational research. Nat Rev Gastroenterol Hepatol  2020; 17(4): 203-22.
 [http://dx.doi.org/10.1038/s41575-019-0255-2]

[24]
Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and barrett’s epithelium. Gastroenterology  2011; 141(5): 1762-72.
 [http://dx.doi.org/10.1053/j.gastro.2011.07.050]

[25]
Jacob F, Salinas RD, Zhang DY, et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell  2020; 180(1): 188-204.e22.
 [http://dx.doi.org/10.1016/j.cell.2019.11.036]

[26]
Sondorp LHJ, Ogundipe VML, Groen AH, et al. Patient-derived papillary thyroid cancer organoids for radioactive iodine refractory screening. Cancers (Basel)  2020; 12(11): 3212.
 [http://dx.doi.org/10.3390/cancers12113212]

[27]
Lee SH, Hu W, Matulay JT, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell  2018; 173(2): 515-528.e17.
 [http://dx.doi.org/10.1016/j.cell.2018.03.017]

[28]
Ukai S, Honma R, Sakamoto N, et al. Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell. Oncogene  2020; 39(50): 7265-78.
 [http://dx.doi.org/10.1038/s41388-020-01492-9]

[29]
Lu Z, Xie J, Wu G, et al. Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation. Nat Med  2017; 23(1): 79-90.
 [http://dx.doi.org/10.1038/nm.4252]

[30]
Yao Y, Xu X, Yang L, et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell  2020; 26(1): 17-26.e6.
 [http://dx.doi.org/10.1016/j.stem.2019.10.010]

[31]
Weeber F, van de Wetering M, Hoogstraat M, et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc Natl Acad Sci USA  2015; 112(43): 13308-11.
 [http://dx.doi.org/10.1073/pnas.1516689112]

[32]
van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell  2015; 161(4): 933-45.
 [http://dx.doi.org/10.1016/j.cell.2015.03.053]

[33]
Buzzelli JN, Ouaret D, Brown G, Allen PD, Muschel RJ. Colorectal cancer liver metastases organoids retain characteristics of original tumor and acquire chemotherapy resistance. Stem Cell Res (Amst)  2018; 27: 109-20.
 [http://dx.doi.org/10.1016/j.scr.2018.01.016]

[34]
Janakiraman H, Zhu Y, Becker SA, et al. Modeling rectal cancer to advance neoadjuvant precision therapy. Intern. J Cancer  2020; 147(5): 1405-18.

[35]
Matano M, Date S, Shimokawa M, et al. Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids. Nat Med  2015; 21(3): 256-62.
 [http://dx.doi.org/10.1038/nm.3802]

[36]
Fujii M, Matano M, Nanki K, Sato T. Efficient genetic engineering of human intestinal organoids using electroporation. Nat Protoc  2015; 10(10): 1474-85.
 [http://dx.doi.org/10.1038/nprot.2015.088]

[37]
Drost J, Clevers H. Organoids in cancer research. Nature Reviews Cancer  2019; 18: 407-18.

[38]
Roper J, Tammela T, Cetinbas NM, et al. In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nat Biotechnol  2017; 35(6): 569-76.
 [http://dx.doi.org/10.1038/nbt.3836]

[39]
O’Rourke KP, Loizou E, Livshits G, et al. Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. Nat Biotechnol  2017; 35(6): 577-82.
 [http://dx.doi.org/10.1038/nbt.3837]

[40]
Fumagalli A, Suijkerbuijk SJE, Begthel H, et al. A surgical orthotopic organoid transplantation approach in mice to visualize and study colorectal cancer progression. Nat Protoc  2018; 13(2): 235-47.
 [http://dx.doi.org/10.1038/nprot.2017.137]

[41]
Fang G, Lu H, Al-Nakashli R, et al. Enabling peristalsis of human colon tumor organoids on microfluidic chips. Biofabrication  2022; 14(1): 015006.
 [http://dx.doi.org/10.1088/1758-5090/ac2ef9]

[42]
Stupar RM. Into the wild: The soybean genome meets its undomesticated relative. Proc Natl Acad Sci USA  2010; 107(51): 21947-8.
 [http://dx.doi.org/10.1073/pnas.1016809108]

[43]
Vlachogiannis G, Hedayat S, Vatsiou A. Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R, Rata M, Koh Dow-Mu, Tunariu N, Collins D, Hulkki-Wilson S, Ragulan C, Spiteri I, Yu Moorcraft S, Chau I, Rao S,Watkins D, Fotiadis N, Bali M, Darvish-Damavandi M, Lote H, et al. Patientderived organoids model treatment response of metastatic gastrointestinal cancers. Science  2018; 23; 359(6378): 920-26.

[44]
Xie BY, Wu AW. Organoid culture of isolated cells from patient-derived tissues with colorectal cancer. Chin Med J (Engl)  2016; 129(20): 2469-75.
 [http://dx.doi.org/10.4103/0366-6999.191782]

[45]
Pasch CA, Favreau PF, Yueh AE, et al. Patient-derived cancer organoid cultures to predict sensitivity to chemotherapy and radiation. Clin Cancer Res  2019; 25(17): 5376-87.
 [http://dx.doi.org/10.1158/1078-0432.CCR-18-3590]

[46]
Ooft SN, Weeber F, Dijkstra KK, et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci Transl Med  2019; 11(513): eaay2574.
 [http://dx.doi.org/10.1126/scitranslmed.aay2574]

[47]
Smith JJ, Strombom P, Chow OS, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol  2019; 5(4): e185896.
 [http://dx.doi.org/10.1001/jamaoncol.2018.5896]

[48]
Ganesh K, Wu C, O’Rourke KP, et al. A rectal cancer organoid platform to study individual responses to chemoradiation. Nat Med  2019; 25(10): 1607-14.
 [http://dx.doi.org/10.1038/s41591-019-0584-2]

[49]
Chen Y, Gao D, Liu H, Lin S, Jiang Y. Drug cytotoxicity and signaling pathway analysis with three-dimensional tumor spheroids in a microwell-based microfluidic chip for drug screening. Anal Chim Acta  2015; 898: 85-92.
 [http://dx.doi.org/10.1016/j.aca.2015.10.006]

[50]
Sobrino A, Phan DTT, Datta R, et al. 3D microtumors in vitro supported by perfused vascular networks. Sci Rep  2016; 6(1): 31589.
 [http://dx.doi.org/10.1038/srep31589]

[51]
Hachey SJ, Movsesyan S, Nguyen QH, et al. An in vitro vascularized micro-tumor model of human colorectal cancer recapitulates in vivo responses to standard-of-care therapy. Lab Chip  2021; 21(7): 1333-51.
 [http://dx.doi.org/10.1039/D0LC01216E]

[52]
Nguyen M, De Ninno A, Mencattini A, et al. Dissecting effects of anti-cancer drugs and cancer-associated fibroblasts by on-chip reconstitution of immunocompetent tumor microenvironments. Cell Rep  2018; 25(13): 3884-3893.e3.
 [http://dx.doi.org/10.1016/j.celrep.2018.12.015]

[53]
Walsh CL, Babin BM, Kasinskas RW, Foster JA, McGarry MJ, Forbes NS. A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics. Lab Chip  2009; 9(4): 545-54.
 [http://dx.doi.org/10.1039/B810571E]

[54]
Sontheimer-Phelps A, Hassell BA, Ingber DE. Modelling cancer in microfluidic human organs-on-chips. Nat Rev Cancer  2019; 19(2): 65-81.
 [http://dx.doi.org/10.1038/s41568-018-0104-6]

[55]
Jenkins RW, Aref AR, Lizotte PH, et al. Ex vivo profiling of PD-1 blockade using organotypic tumor Spheroids Ex vivo profiling of immune checkpoint blockade. Cancer Discov  2018; 8(2): 196-215.
 [http://dx.doi.org/10.1158/2159-8290.CD-17-0833]

[56]
Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell  2018; 172(1-2): 373-386.e10.
 [http://dx.doi.org/10.1016/j.cell.2017.11.010]

[57]
Jabs J, Zickgraf FM, Park J, et al. Screening drug effects in patient‐derived cancer cells links organoid responses to genome alterations. Mol Syst Biol  2017; 13(11): 955.
 [http://dx.doi.org/10.15252/msb.20177697]

[58]
Onozato D, Yamashita M, Nakanishi A, et al. Generation of intestinal organoids suitable for pharmacokinetic studies from human induced pluripotent stem cells. Drug Metab Dispos  2018; 46(11): 1572-80.
 [http://dx.doi.org/10.1124/dmd.118.080374]

[59]
Onozato D, Yamashita M, Fukuyama R, et al. Efficient generation of cynomolgus monkey induced pluripotent stem cell-derived intestinal organoids with pharmacokinetic functions. Stem Cells Dev  2018; 27(15): 1033-45.
 [http://dx.doi.org/10.1089/scd.2017.0216]

[60]
Kostadinova R, Boess F, Applegate D, et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol Appl Pharmacol  2013; 268(1): 1-16.
 [http://dx.doi.org/10.1016/j.taap.2013.01.012]

[61]
Meng Q. Three-dimensional culture of hepatocytes for prediction of drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol  2010; 6(6): 733-46.
 [http://dx.doi.org/10.1517/17425251003674356]

[62]
Katsuda T, Kawamata M, Hagiwara K, et al. Conversion of terminally committed hepatocytes to culturable bipotent progenitor cells with regenerative capacity. Cell Stem Cell  2017; 20(1): 41-55.
 [http://dx.doi.org/10.1016/j.stem.2016.10.007]

[63]
Li A, Zhang T, Zheng M, Liu Y, Chen Z. Exosomal proteins as potential markers of tumor diagnosis. J Hematol Oncol  2017; 10(1): 175.
 [http://dx.doi.org/10.1186/s13045-017-0542-8]

[64]
Eder A, Vollert I, Hansen A, Eschenhagen T. Human engineered heart tissue as a model system for drug testing. Adv Drug Deliv Rev  2016; 96: 214-24.
 [http://dx.doi.org/10.1016/j.addr.2015.05.010]

[65]
Voges HK, Mills RJ, Elliott DA, Parton RG, Porrello ER, Hudson JE. Development of a human cardiac organoid injury model reveals innate regenerative potential. Development  2017; 144(6): dev.143966.
 [http://dx.doi.org/10.1242/dev.143966]

[66]
Takasato M, Er PX, Chiu HS, et al. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature  2015; 526(7574): 564-8.
 [http://dx.doi.org/10.1038/nature15695]

[67]
Sato T, Clevers H. SnapShot, growing organoids from stem cells. Cell  2015; 161(7): 1700-1700.e1.
 [http://dx.doi.org/10.1016/j.cell.2015.06.028]

[68]
Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science  2015; 348(6230): 124-8.
 [http://dx.doi.org/10.1126/science.aaa1348]

[69]
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med  2015; 372(26): 2509-20.
 [http://dx.doi.org/10.1056/NEJMoa1500596]

[70]
Nozaki K, Mochizuki W, Matsumoto Y, et al. Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes. J Gastroenterol  2016; 51(3): 206-13.
 [http://dx.doi.org/10.1007/s00535-016-1170-8]

[71]
Finnberg NK, Gokare P, Lev A, et al. Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures. Oncotarget  2017; 8(40): 66747-57.
 [http://dx.doi.org/10.18632/oncotarget.19965]

[72]
Zumwalde NA, Haag JD, Sharma D, et al. Analysis of immune cells from human mammary ductal epithelial organoids reveals vδ2+ t cells that efficiently target breast carcinoma cells in the presence of bisphosphonatebisphosphonate activates human breast t cells. Cancer Prev Res (Phila)  2016; 9(4): 305-16.
 [http://dx.doi.org/10.1158/1940-6207.CAPR-15-0370-T]

[73]
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med  2008; 359(17): 1757-65.
 [http://dx.doi.org/10.1056/NEJMoa0804385]

[74]
Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol  2008; 26(10): 1626-34.
 [http://dx.doi.org/10.1200/JCO.2007.14.7116]

[75]
Peeters M, Oliner KS, Parker A, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase iii study of metastatic colorectal cancer. Clin Cancer Res  2013; 19(7): 1902-12.
 [http://dx.doi.org/10.1158/1078-0432.CCR-12-1913]

[76]
Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer  2009; 101(4): 715-21.
 [http://dx.doi.org/10.1038/sj.bjc.6605177]

[77]
Malik AM, Miguez RA, Li X, Ho YS, Feldman EL, Barmada SJ. Matrin 3-dependent neurotoxicity is modified by nucleic acid binding and nucleocytoplasmic localization. eLife  2018; 7: e35977.
 [http://dx.doi.org/10.7554/eLife.35977]

[78]
Zhai Z, Yu X, Yang B, et al. Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. Semin Cell Dev Biol  2017; 64: 107-15.
 [http://dx.doi.org/10.1016/j.semcdb.2016.08.033]

[79]
Fujii M, Shimokawa M, Date S, et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell  2016; 18(6): 827-38.
 [http://dx.doi.org/10.1016/j.stem.2016.04.003]

[80]
Drost J, van Jaarsveld RH, Ponsioen B, et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature  2015; 521(7550): 43-7.
 [http://dx.doi.org/10.1038/nature14415]

[81]
IJspeert JEG, Vermeulen L, Meijer GA, Dekker E. Serrated neoplasia—role in colorectal carcinogenesis and clinical implications. Nat Rev Gastroenterol Hepatol  2015; 12(7): 401-9.
 [http://dx.doi.org/10.1038/nrgastro.2015.73]

[82]
Janda CY, Dang LT, You C, et al. Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signalling. Nature  2017; 545(7653): 234-7.
 [http://dx.doi.org/10.1038/nature22306]

[83]
Mihara E, Hirai H, Yamamoto H, et al. Active and water-soluble form of lipidated Wnt protein is maintained by a serum glycoprotein afamin/α-albumin. eLife  2016; 5(5): e11621.
 [http://dx.doi.org/10.7554/eLife.11621]

[84]
Chaturvedi S, Verma A, Saharan VA. Lipid drug carriers for cancer therapeutics: An insight into lymphatic targeting, P-gp, CYP3A4 modulation and bioavailability enhancement. Adv Pharm Bull  2020; 10(4): 524-41.
 [http://dx.doi.org/10.34172/apb.2020.064]

[85]
Deshmukh R, Prajapati M, Harwansh RK. A review on emerging targeted therapies for the management of metastatic colorectal cancers. Med Oncol  2023; 40(6): 159.
 [http://dx.doi.org/10.1007/s12032-023-02020-x]

[86]
Rizwanullah M, Ahmad MZ, Garg A, Ahmad J. Advancement in design of nanostructured lipid carriers for cancer targeting and theranostic application. Biochim Biophys Acta, Gen Subj  2021; 1865(9): 129936.
 [http://dx.doi.org/10.1016/j.bbagen.2021.129936]

[87]
Agrawal KK, Murti Y. Jyoti, Agrawal N, Gupta T. In silico studies of bioactive compounds from hibiscus rosa-sinensis against her2 and esr1 for breast cancer treatment. International Journal of Pharmaceutical Sciences and Nanotechnology  2021; 14(6): 5665-71.
 [http://dx.doi.org/10.37285/ijpsn.2021.14.6.3]

[88]
Luo L, Ma Y, Zheng Y, Su J, Huang G. Application progress of organoids in colorectal cancer. Front Cell Dev Biol  2022; 10: 815067.
 [http://dx.doi.org/10.3389/fcell.2022.815067]

[89]
Lo Y-H, Karlsson K, Kuo CJ. Applications of organoids for cancer biology and precision medicine. Nat Can  2020; 1(8): 761-73.
 [http://dx.doi.org/10.1038/s43018-020-0102-y]

Rights & Permissions Print Cite

Article Metrics

24

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0115748855266739230919110125	Print ISSN 1574-8855
Publisher Name Bentham Science Publisher	Online ISSN 2212-3903

Current Drug Therapy

Organoids Research for Colorectal Cancer: Promising Approach for Precision Medicine, their Applications and Future Perspectives

Abstract

Graphical Abstract

Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)

Current Drug Therapy

Organoids Research for Colorectal Cancer: Promising Approach for Precision Medicine, their Applications and Future Perspectives

Abstract

Graphical Abstract

Call for Papers in Thematic Issues

Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)

Related Journals

Related Books

Related Articles